Holen Sie sich die Stockscreener-App
4.34
12.85%
-0.33
Schlusskurs vom Vortag:
$4.67
Offen:
$4.8
24-Stunden-Volumen:
151.43K
Relative Volume:
4.04
Marktkapitalisierung:
$3.87M
Einnahmen:
$61,000
Nettoeinkommen (Verlust:
$-5.46M
KGV:
-0.6636
EPS:
-6.54
Netto-Cashflow:
$-6.76M
1W Leistung:
-22.18%
1M Leistung:
+9.12%
6M Leistung:
+9.96%
1J Leistung:
-35.80%
1-Tages-Spanne:
$3.98
$5.28
1-Wochen-Bereich:
$3.98
$5.28
52-Wochen-Spanne:
$3.03
$14.80
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Firmenname
Titan Pharmaceuticals Inc De
Sektor
Branche
Telefon
(650) 244-4990
Adresse
400 OYSTER POINT BLVD, SAN FRANCISCO
Vergleichen Sie TTNP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
4.25 | 4.78M | 61,000 | -5.46M | -6.76M | -6.54 |
|
ONC
Beigene Ltd Adr
|
231.96 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.88 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
593.44 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.86 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-06-26 | Eingeleitet | Maxim Group | Buy |
| 2017-11-10 | Herabstufung | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Aktie (TTNP) Neueste Nachrichten
HOPE Therapeutics Lands $7.8M Deal to Build National Mental Health Network with Ketamine Treatment Centers - Stock Titan
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - Stock Titan
NRXP Reveals Major Mental Health Expansion Plans at Exclusive Mar-A-Lago Investor Event - Stock Titan
Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan
FDA Awards NRx Pharmaceuticals $4.3M Waiver for Revolutionary Suicidal Depression Treatment - Stock Titan
Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package - Stock Titan
Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan
Major UK Retail Breakthrough: Sonoma's Natural Acne Treatment to Roll Out Across 1,200 Leading Pharmacies - Stock Titan
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan
Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan
US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga
Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan
Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan
Keros Eyes Potential Sale: Board Weighs Strategic Options Amid Investor Interest - Stock Titan
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan
Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan
Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan
BioCryst Awards Strategic RSU Grants to 10 New Employees: Growth Plans Revealed - Stock Titan
Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan
Dogwood Therapeutics Saves Nasdaq Status: $17.5M Cash, Zero Debt After Major Financial Overhaul - Stock Titan
Terns Pharmaceuticals Attracts Top Talent with 611,000-Share Equity Package - Stock Titan
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
Exclusive: ANI Pharmaceuticals CEO Reveals Growth Strategy at Major Ophthalmology Conference - Stock Titan
Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
NRx Pharmaceuticals Slashes Losses by 33% While Securing $300M+ Potential Deal - Stock Titan
Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan
NRx Pharmaceuticals Readies Major Financial Update: Full Year Results and Strategic Outlook Coming March 17 - Stock Titan
Armata CEO Dr. Deborah Birx Takes Center Stage at Major Bacteriophage Summit - Stock Titan
Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - Stock Titan
How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan
Will Amphastar Reveal New Strategic Insights at Upcoming Barclays Healthcare Conference? - Stock Titan
Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - Stock Titan
Elite Pharmaceuticals Triples Manufacturing Potential With High-Speed Facility Launch - StockTitan
Tenaya's $52.5M Offering: What Does This Massive 75M Share Dilution Mean for TNYA Investors? - Stock Titan
Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - Stock Titan
Finanzdaten der Titan Pharmaceuticals Inc De-Aktie (TTNP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.56%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):